Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 221Polycystic Ovary Syndrome 36Endometrial Neoplasms 15Ovarian Neoplasms 13Infertility 11Neoplasm Metastasis 9Carcinoma, Intraductal, Noninfiltrating 7Fallopian Tube Neoplasms 6Neoplasms 5Breast Diseases 5Triple Negative Breast Neoplasms 4Osteoporosis 4Leiomyoma 4Infertility, Female 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Recurrence 3Obesity 3Breast Cancer Metastatic 3Anovulation 3Uterine Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Pain 2Leiomyosarcoma 2HR Positive HER2 Negative Advanced Breast Cancer 2

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone-sensitive Metastatic Breast Cancer × Letrozole × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡